Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection

Claudio Zavaglia, Enrico Silini, Alessandra Mangia, Aldo Airoldi, Valeria Piazzolla, Marcello Vangeli, Rosa Stigliano, Antonella Foschi, Chiara Mazzarelli, Carmine Tinelli

Research output: Contribution to journalArticle

Abstract

Aims: Aim of this study was to assess if host (immunogenetic traits, age, sex), exogenous (alcohol) or viral factors (viral type, past HBV infection) might affect the progression of chronic hepatitis C to liver decompensation or the development of HCC in a cohort of patients exposed to a single blood transfusion prior to the introduction of anti-HCV screening. Methods: Two hundred and forty-eight patients with a history of a single exposure to blood or blood products prior to 1990 were retrospectively considered. Patients were devoid of other risk factors of liver disease or immunosuppression and naïve to antiviral therapies. Eight baseline variables were assessed: age at transfusion, sex, HBV core antibody, immunogenetic profile (DRB1*11, DRB1*1104, DRB1*07), HCV genotype and alcohol consumption. Results: The follow-up was 22 (SD: 11) years. Sixty-eight patients (27%) progressed to hepatic decompensation over a median period of 22.5 years (IQR: 14-30) and 41 patients (16%) developed HCC over a median period of 31 years (IQR: 24-38). The cumulative incidence of liver failure was 0.4% (95% CI: 0.1-3.1), 4.9% (95% CI: 2.6-9.3) and 16.2% (95% CI: 10.4-24.7) at 10, 20 and 30 years after blood transfusion respectively. By univariate analysis, only age at transfusion was correlated with the risk of decompensation. Stratifying the age of transfusion by tertiles, the incidence of hepatic decompensation was 0.7% per year in patients transfused at ≤24 years of age as compared to 1.2% and 1.9% per year in those transfused at 25-35 and >36 years of age respectively (HR: 5.5, 95% CI: 2.78-10.7, P 36 compared to ≤24 years, HR: 10.3, 95% CI: 3.9-26.9, P 

Original languageEnglish
Pages (from-to)308-316
Number of pages9
JournalLiver International
Volume34
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Hepatocellular Carcinoma
Liver
Infection
Immunogenetics
Blood Transfusion
Incidence
Liver Failure
Chronic Hepatitis C
Alcohol Drinking
Immunosuppression
Antiviral Agents
Liver Diseases
Genotype
Alcohols
Antibodies
Therapeutics

Keywords

  • Blood transfusion
  • Chronic hepatitis C
  • HCV
  • Hepatic decompensation
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. / Zavaglia, Claudio; Silini, Enrico; Mangia, Alessandra; Airoldi, Aldo; Piazzolla, Valeria; Vangeli, Marcello; Stigliano, Rosa; Foschi, Antonella; Mazzarelli, Chiara; Tinelli, Carmine.

In: Liver International, Vol. 34, No. 7, 2014, p. 308-316.

Research output: Contribution to journalArticle

Zavaglia, Claudio ; Silini, Enrico ; Mangia, Alessandra ; Airoldi, Aldo ; Piazzolla, Valeria ; Vangeli, Marcello ; Stigliano, Rosa ; Foschi, Antonella ; Mazzarelli, Chiara ; Tinelli, Carmine. / Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. In: Liver International. 2014 ; Vol. 34, No. 7. pp. 308-316.
@article{e9eb8cbbc21a446f8f4a1992502f3291,
title = "Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection",
abstract = "Aims: Aim of this study was to assess if host (immunogenetic traits, age, sex), exogenous (alcohol) or viral factors (viral type, past HBV infection) might affect the progression of chronic hepatitis C to liver decompensation or the development of HCC in a cohort of patients exposed to a single blood transfusion prior to the introduction of anti-HCV screening. Methods: Two hundred and forty-eight patients with a history of a single exposure to blood or blood products prior to 1990 were retrospectively considered. Patients were devoid of other risk factors of liver disease or immunosuppression and na{\"i}ve to antiviral therapies. Eight baseline variables were assessed: age at transfusion, sex, HBV core antibody, immunogenetic profile (DRB1*11, DRB1*1104, DRB1*07), HCV genotype and alcohol consumption. Results: The follow-up was 22 (SD: 11) years. Sixty-eight patients (27{\%}) progressed to hepatic decompensation over a median period of 22.5 years (IQR: 14-30) and 41 patients (16{\%}) developed HCC over a median period of 31 years (IQR: 24-38). The cumulative incidence of liver failure was 0.4{\%} (95{\%} CI: 0.1-3.1), 4.9{\%} (95{\%} CI: 2.6-9.3) and 16.2{\%} (95{\%} CI: 10.4-24.7) at 10, 20 and 30 years after blood transfusion respectively. By univariate analysis, only age at transfusion was correlated with the risk of decompensation. Stratifying the age of transfusion by tertiles, the incidence of hepatic decompensation was 0.7{\%} per year in patients transfused at ≤24 years of age as compared to 1.2{\%} and 1.9{\%} per year in those transfused at 25-35 and >36 years of age respectively (HR: 5.5, 95{\%} CI: 2.78-10.7, P 36 compared to ≤24 years, HR: 10.3, 95{\%} CI: 3.9-26.9, P ",
keywords = "Blood transfusion, Chronic hepatitis C, HCV, Hepatic decompensation, Hepatocellular carcinoma",
author = "Claudio Zavaglia and Enrico Silini and Alessandra Mangia and Aldo Airoldi and Valeria Piazzolla and Marcello Vangeli and Rosa Stigliano and Antonella Foschi and Chiara Mazzarelli and Carmine Tinelli",
year = "2014",
doi = "10.1111/liv.12502",
language = "English",
volume = "34",
pages = "308--316",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection

AU - Zavaglia, Claudio

AU - Silini, Enrico

AU - Mangia, Alessandra

AU - Airoldi, Aldo

AU - Piazzolla, Valeria

AU - Vangeli, Marcello

AU - Stigliano, Rosa

AU - Foschi, Antonella

AU - Mazzarelli, Chiara

AU - Tinelli, Carmine

PY - 2014

Y1 - 2014

N2 - Aims: Aim of this study was to assess if host (immunogenetic traits, age, sex), exogenous (alcohol) or viral factors (viral type, past HBV infection) might affect the progression of chronic hepatitis C to liver decompensation or the development of HCC in a cohort of patients exposed to a single blood transfusion prior to the introduction of anti-HCV screening. Methods: Two hundred and forty-eight patients with a history of a single exposure to blood or blood products prior to 1990 were retrospectively considered. Patients were devoid of other risk factors of liver disease or immunosuppression and naïve to antiviral therapies. Eight baseline variables were assessed: age at transfusion, sex, HBV core antibody, immunogenetic profile (DRB1*11, DRB1*1104, DRB1*07), HCV genotype and alcohol consumption. Results: The follow-up was 22 (SD: 11) years. Sixty-eight patients (27%) progressed to hepatic decompensation over a median period of 22.5 years (IQR: 14-30) and 41 patients (16%) developed HCC over a median period of 31 years (IQR: 24-38). The cumulative incidence of liver failure was 0.4% (95% CI: 0.1-3.1), 4.9% (95% CI: 2.6-9.3) and 16.2% (95% CI: 10.4-24.7) at 10, 20 and 30 years after blood transfusion respectively. By univariate analysis, only age at transfusion was correlated with the risk of decompensation. Stratifying the age of transfusion by tertiles, the incidence of hepatic decompensation was 0.7% per year in patients transfused at ≤24 years of age as compared to 1.2% and 1.9% per year in those transfused at 25-35 and >36 years of age respectively (HR: 5.5, 95% CI: 2.78-10.7, P 36 compared to ≤24 years, HR: 10.3, 95% CI: 3.9-26.9, P 

AB - Aims: Aim of this study was to assess if host (immunogenetic traits, age, sex), exogenous (alcohol) or viral factors (viral type, past HBV infection) might affect the progression of chronic hepatitis C to liver decompensation or the development of HCC in a cohort of patients exposed to a single blood transfusion prior to the introduction of anti-HCV screening. Methods: Two hundred and forty-eight patients with a history of a single exposure to blood or blood products prior to 1990 were retrospectively considered. Patients were devoid of other risk factors of liver disease or immunosuppression and naïve to antiviral therapies. Eight baseline variables were assessed: age at transfusion, sex, HBV core antibody, immunogenetic profile (DRB1*11, DRB1*1104, DRB1*07), HCV genotype and alcohol consumption. Results: The follow-up was 22 (SD: 11) years. Sixty-eight patients (27%) progressed to hepatic decompensation over a median period of 22.5 years (IQR: 14-30) and 41 patients (16%) developed HCC over a median period of 31 years (IQR: 24-38). The cumulative incidence of liver failure was 0.4% (95% CI: 0.1-3.1), 4.9% (95% CI: 2.6-9.3) and 16.2% (95% CI: 10.4-24.7) at 10, 20 and 30 years after blood transfusion respectively. By univariate analysis, only age at transfusion was correlated with the risk of decompensation. Stratifying the age of transfusion by tertiles, the incidence of hepatic decompensation was 0.7% per year in patients transfused at ≤24 years of age as compared to 1.2% and 1.9% per year in those transfused at 25-35 and >36 years of age respectively (HR: 5.5, 95% CI: 2.78-10.7, P 36 compared to ≤24 years, HR: 10.3, 95% CI: 3.9-26.9, P 

KW - Blood transfusion

KW - Chronic hepatitis C

KW - HCV

KW - Hepatic decompensation

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84904461276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904461276&partnerID=8YFLogxK

U2 - 10.1111/liv.12502

DO - 10.1111/liv.12502

M3 - Article

C2 - 24529078

AN - SCOPUS:84904461276

VL - 34

SP - 308

EP - 316

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 7

ER -